[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-bleeding":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,90,120,156,186,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100640491","measurement-of-urinary-hormones-in-patients-with-abnormal-uterine-bleeding-to-study-uterine-cancer-progression-100640491",false,"NCT07581288","Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression","Quantitative Hormonal Biomarkers of Uterine Cancer Progression in Patients With Abnormal Uterine Bleeding","MIRA","Inclusion Criteria:\n\n* 35 years and older\n* Have experienced AUB\n\nExclusion Criteria:\n\n* Currently pregnant or become pregnant during their participation\n* Previous surgeries impairing the menstrual cycle (e.g. hysterectomy, bilateral oophorectomy)\n* Currently or in the previous 3 months on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, hormone replacement, etc.)","FEMALE","35 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor. The investigators will measure recruitment rate, attrition and cycle collection completeness of data. The investigators will evaluate menstrual health literacy at baseline and at the conclusion of the study.",[25,26,27,28,29,30,31,32],"Uterine Bleeding","Uterine Cancer","Uterine Neoplasms","Endometrial Cancer","Endometrial Hyperplasia","Endometrial Intraepithelial Neoplasia","Menstrual Cycle","Reproductive Endocrinology",[34,35,26,36,37,38,39,40,41,42],"Digital Health","Urinary Hormones","Abnormal Uterine Bleeding","Menstrual Cycle Tracking","At-home monitoring","Follicle Stimulating Hormone","Luteinizing Hormone","Estrogen","Progesterone","NOT_YET_RECRUITING","2026-05-06",{"date":46,"type":47},"2026-05-12","ACTUAL",{"date":49,"type":21},"2026-05",{"date":51,"type":21},"2026-09",{"name":53,"class":54},"University of British Columbia","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":55},"100598505","videos-to-aid-decision-making-for-fibroid-treatment-100598505","NCT07072364","Videos to Aid Decision Making for Fibroid Treatment","The Use of Video Aids Versus Usual Care for Reduction in Decisional Conflict in Fibroid Treatment","Fibroid AUB","Inclusion Criteria:\n\n* Diagnosis of uterine fibroids\n* Scheduled appointment to discuss management of fibroids in an outpatient clinical site associated with the Hospital of the University of Pennsylvania\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>55\n* Uterine or cervical cancer\n* Cervical dysplasia grade 2-3 within the last 12 mo\n* Pregnancy\n* Menopause\n* Decision made prior to the study intake to have a surgical procedure for treatment of fibroids","ALL","18 Years","55 Years",{"count":68,"type":21},154,"INTERVENTIONAL",[71],"NA","Uterine fibroids are a common condition that can cause heavy and\u002For painful menstrual bleeding. There are many treatment options, but they vary in efficacy, side effects, short-term recovery and long-term implications for future fertility. Patients can have difficulty deciding between these options. In this study, the investigators will randomly assign patients seeking treatment for fibroids to receive an educational video on fibroids and their treatment, versus usual care (no video). The investigators will assess their decisional conflict with and without exposure to the video using a validated survey to see if exposure to the educational video helps them make decisions.",[25,74],"Decision Aid",[76,77,78,79],"Abnormal uterine bleeding","Uterine fibroids","Decisional Conflict Scale","Educational videos","RECRUITING","2026-04-29",{"date":83,"type":47},"2026-05-01",{"date":85,"type":47},"2025-03-12",{"date":87,"type":21},"2026-07",{"name":89,"class":54},"University of Pennsylvania",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":69,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":55},"100626142","the-effect-of-uterine-manipulator-use-during-abdominal-hysterectomy-on-postoperative-sexual-function-100626142","NCT07431788","The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual Function","A Prospective Randomized Controlled Trial Evaluating the Impact of Uterine Manipulator Use During Total Abdominal Hysterectomy on Postoperative Female Sexual Function","UMAH","Inclusion Criteria:\n\n* Women aged ≥18 years\n* Planned total abdominal hysterectomy for benign indications\n* Sexually active within the last 4 weeks\n* Able to complete the Female Sexual Function Index (FSFI) questionnaire\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Gynecologic malignancy\n* Major additional pelvic reconstructive surgery\n* Severe psychiatric or neurologic disorder\n* Inability to complete follow-up assessments",{"count":99,"type":21},60,[71],"This prospective, single-center, randomized controlled trial aims to evaluate the effect of uterine manipulator use during total abdominal hysterectomy on postoperative female sexual function at 3 months, assessed by the Female Sexual Function Index (FSFI). Secondary outcomes include operative time, perioperative hemoglobin change, postoperative pain (VAS), hospital stay duration, and 30-day complications.",[103,104,25],"Leiomyoma (Uterine Fibroids)","Adenomyoma of Uterus",[106,107,108,109,110],"Hysterectomy","Uterin Manipulator","Female Sexual Function","FSFI","Randomized Controlled Trial","2026-03-02",{"date":113,"type":47},"2026-03-03",{"date":111,"type":47},{"date":116,"type":21},"2027-02",{"name":118,"class":119},"Erkan Gol","OTHER_GOV",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":17,"minAge":65,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":69,"phases":132,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":55},"100456525","platelet-rich-plasma-for-uterine-scar-100456525","NCT05224726","Platelet Rich Plasma for Uterine Scar","Platelet Rich Plasma for the Treatment of Uterine Scar","AA-PRP","Inclusion criteria:\n\n* Women undergoing elective cesarean delivery\n* Term pregnancy (≥37 weeks of gestation)\n\nExclusion criteria:\n\n* Thrombocytopenia (CBC Platelet count \\\u003C70,000)\n* Connective tissue disease\n* Uterine scars other than cesarean (s\u002Fp myomectomy, s\u002Fp cornual resection)\n* Malformed uterus (unicornuate, bicornuate, didelphic)",true,"52 Years",{"count":131,"type":21},40,[71],"When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.",[135,25,136,137],"Cesarean Section Complications","Pelvic Pain","Menstrual Irregularity",[139,140,141,142,143,144,145,146],"uterine scar defect","cesarean delivery","pelvic pain","spotting","niche","cesarean section complication","uterine scar","Platelet Rich Plasma (PRP)","2025-08-24",{"date":149,"type":47},"2025-08-26",{"date":151,"type":47},"2025-07-19",{"date":153,"type":21},"2028-07-01",{"name":155,"class":54},"The University of Texas Health Science Center, Houston",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":55},"100589335","ultrasound-transformation-of-myomas-during-relugolix-estradiol-norethisterone-treatment-the-mysaturn-study-100589335","NCT06953076","Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study","MyomaS Aspect Transformation at Ultrasound During Relugolix Estradiol Noretisterone Treatment: MySaturn Study","MySaturn","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Pre-menopausal status.\n3. Ultrasound diagnosis of benign myometrial lesion.\n4. Symptomatic patients presenting with abnormal uterine bleeding (menorrhagia\u002Fmetrorrhagia).\n5. Availability of ultrasound images in digital format.\n\nExclusion Criteria:\n\n1. Patient refusal.\n2. Age \\\u003C 18 years.\n3. Postmenopausal women.\n4. Myometrial lesion ≤ 10 mm.\n5. Myometrial formation suspected of malignancy on ultrasound (e.g., STUMP - Uterine Leiomyosarcoma).\n6. Asymptomatic patients with uterine fibromatosis.\n7. Personal history of malignant or premalignant uterine neoplasia (e.g., STUMPs, leiomyosarcoma, atypical endometrial hyperplasia, endometrial carcinoma, cervical carcinoma).\n8. Patients with ovarian pathology.\n9. Patients currently undergoing treatment for another malignancy.\n10. Patients lacking available digital ultrasound images or whose image quality is insufficient to adequately characterize the target lesion's ultrasound features",{"count":165,"type":21},111,"Uterine fibroids are benign tumors originating from the uterine muscle, affecting up to 70% of women by their 50s. Risk factors include African descent, nulliparity, obesity, and diabetes. While many fibroids are asymptomatic, 25-50% of affected women experience symptoms like heavy menstrual bleeding, pelvic pain, and pressure-related issues. Accurate diagnosis and differentiation from rare malignant tumors (e.g., uterine sarcomas) remain challenging, particularly before surgery.\n\nUltrasound is the first-line tool for evaluating fibroids, with specific features (e.g., shape, vascularity) helping distinguish benign from suspicious lesions. The MUSA guidelines standardize ultrasound terminology for myometrial assessments. Current treatment options vary based on symptoms and malignancy risk. Among pharmacologic options, the combination of relugolix, estradiol, and norethisterone has shown efficacy in reducing bleeding and pain in symptomatic fibroids, with a favorable safety profile. However, its impact on fibroid morphology and ultrasound appearance is not yet well understood.",[25,168,169,27],"Uterine Leiomyomas","Uterine Hemorrhage",[171,172,173,174,175,176],"myomas","uterine bleeding","fibroids","relugolix","ormonal therapy","smooth muscle cells tumor","2025-08-15",{"date":179,"type":47},"2025-08-17",{"date":181,"type":47},"2025-05-02",{"date":183,"type":21},"2027-05-02",{"name":185,"class":54},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":69,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":55},"100462651","phase-3-iv-iron-trial-for-anemia-related-to-uterine-bleeding-in-female-patients-presenting-to-the-emergency-department-100462651","NCT05304442","IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department","Intravenous Ferric Derisomaltose for Moderate to Severe Anemia Due to Uterine Bleeding in the Emergency Department: a Randomized Trial","Inclusion Criteria:\n\n* Sub-acute or chronic uterine blood loss;\n* Moderate to Severe Anemia, defined as Hgb less than or equal to 9.0 g\u002Fdl;\n* Iron deficiency: Serum ferritin less than or equal to 30 ng\u002FmL;\n* Eligible for discharge from the ED following treatment;\n* Patient able to return for planned follow-up visits at 3 and 6 weeks;\n* Patient able to be reached by telephone;\n* Willing and able to provide consent for participation.\n\nExclusion Criteria:\n\n* Patient requiring hospitalization for any reason;\n* Pregnant or nursing;\n* Incarcerated\u002FPrisoner;\n* Weight \\\u003C 50 kg;\n* History of hypersensitivity reactions, as specified, known hypersensitivity to any formulation of parenteral iron;\n* History of any anaphylactic allergy;\n* Recent receipt of IV iron, erythropoiesis-stimulating agents;\n* Erythropoiesis-stimulating agent use within 8 weeks prior to ED visit;\n* Parenteral iron within 4 weeks prior to ED visit;\n* Scheduled\u002Fplanned use of parenteral iron or ESA during study period;\n* Receipt of blood transfusion at index visit;\n* Planned elective major surgery during study period;\n* Other current or recent hematologic therapy, as specified;\n* Current or planned use of antithrombotic therapy (antiplatelet agents or anticoagulants) within study period (Non-aspirin NSAIDs are NOT a contraindication);\n* Known bleeding disorder platelets \\\u003C 100,000';\n* Other significant underlying comorbidity, as specified:\n* Active rheumatologic disease, or rheumatologist disease requiring treatment, such as rheumatoid arthritis, systemic lupus erythematosus, or mixed connective tissue disease;\n* Acute heart failure or NYHA II-IV chronic heart failure;\n* Inflammatory bowel disease;\n* Cirrhosis or Decompensated liver disease;\n* Chronic kidney disease, stage III or greater (eGFR \\\u003C 60);\n* Current Systemic Infection (e.g. pneumonia, pelvic inflammatory disease, pyelonephritis). \\*Cystitis or cervicitis is NOT an exclusion\n* Any other medical or surgical condition that in the opinion of the treating physician may result in patient being unsuitable for trial participation","65 Years",{"count":131,"type":21},[196],"PHASE3","The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.",[199,25],"Anemia, Iron Deficiency",[201,202,203,25],"IV Iron","Emergency Department","Iron Deficiency Anemia","2024-12-03",{"date":206,"type":47},"2024-12-05",{"date":208,"type":47},"2022-09-15",{"date":210,"type":21},"2025-04",{"name":212,"class":54},"Baylor College of Medicine",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":69,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":55},"100539771","impact-of-single--versus-double-layer-hysterotomy-closure-on-cesarean-niche-development-a-randomized-controlled-trial-100539771","NCT06308172","Impact of Single- Versus Double-layer Hysterotomy Closure on Cesarean Niche Development: a Randomized Controlled Trial","Inclusion Criteria:\n\n* nulliparous\n* singleton\n* age 18-45\n* spontaneous pregnancy or autologous assisted fertilization\n* gestational age 38-40 weeks\n* elective C-section\n* informed consent\n\nExclusion Criteria:\n\n* coagulopathy\n* autoimmune diseases\n* gestational diabetes\n* anticoagulant therapy\n* immunosuppressive therapy\n* endometriosis\n* uterine fibromatosis\n* spontaneous labour\n* connective tissue diseases",{"count":220,"type":21},150,[71],"The objective of this randomized monocentric study is to assess potential variations in the incidence and severity of isthmocele morbidity among women undergoing cesarean section with either single or double-layer closure of the hysterotomy. Our primary outcome aims to investigate whether there is a reduction in the median duration of intermenstrual spotting in patients belonging to the two respective closure groups",[224,25,225,226,135],"Cesarean Section; Dehiscence","Uterus; Scar","Uterus Abnormal","2024-03-06",{"date":229,"type":47},"2024-03-13",{"date":231,"type":47},"2021-12-01",{"date":233,"type":21},"2026-12-01",{"name":235,"class":54},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"]